医学院
|
|
|
|
导师代码: |
20107
|
导师姓名: |
钟磊
|
性 别: |
男 |
特 称: |
|
职 称: |
副教授
|
学 位: |
理学博士学位
|
属 性: |
专职 |
电子邮件: |
zhl7235301@163.com
|
|
|
学术经历:
|
|
2009.09-2012.06,四川大学,华西药学院,药剂学,硕士;
2012.09-2015.06,四川大学,生物治疗国家重点实验室,化学生物学,博士;
2015.07-2019.03,电子科技大学附属医院·四川省人民医院,助理研究员;
2015.10-2019.03,四川大学,生物治疗国家重点实验室,博士后(在职);
2017.01-2021.12,电子科技大学医学院,讲师;
2019.04至今,电子科技大学附属医院·四川省人民医院,副研究员;
2022.01至今,电子科技大学医学院,副教授;
2022.05-2023.06,瑞典乌普萨拉大学,访问学者。
|
|
个人简介:
|
|
钟磊,博士,副教授/副研究员,硕士生导师,四川省省级人才计划入选者,四川省卫健委第十四批学术技术带头人后备人选,第二届中国药理学会治疗药物监测研究专委会青年委员会委员,四川省抗癌协会肿瘤临床药学专委会常务委员,四川省药理学学会治疗药物监测研究专委会常务委员,四川省药理学学会理事会理事。2012年6月毕业于四川大学华西药学院药剂学专业,获理学硕士学位;2015年6月毕业于四川大学生物治疗国家重点实验室化学生物学专业,获理学博士学位;2015年7月入职电子科技大学附属医院·四川省人民医院,主要从事抗肿瘤靶向药物研发和肿瘤耐药机制的研究工作。
|
|
科研项目:
|
|
近年来主持包括国家自然科学基金项目、中国博士后面上项目、四川省科技厅项目、四川省卫健卫课题、成都市科技局项目、中央高校基金,以及吴阶平基金等在内的各级科研项目10余项。
|
|
研究成果:
|
|
发表学术论文50余篇,其中,以一作或通讯作者身份发表SCI论文近30篇,IF>5分16篇,最高影响因子40.8,他引1000余次;申请发明专利4项,现已授权3项;作为项目完成人获四川省医学科技一等奖和二等奖各1项。代表性论文如下:
1. Ma Tingnan, et al. SETDB1: Progress and prospects in cancer treatment potential and inhibitor research. Bioorg Chem, 2024, 145: 107219. (通讯作者)
2. Hou Yingying, et al. Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies. NPJ Vaccines, 2024, 9 (1): 77. (并列通讯)
3. Zhong Lei, et al. Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study. Signal Transduct Target Ther, 2023, 8 (1): 363.
4. Peng Haoyuan, et al. Ganoderma lucidum: Current advancements of characteristic components and experimental progress in anti-liver fibrosis. Front Pharmacol, 2023, 13: 1094405. (并列一作)
5. Lu X, Zhong L, et al. Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells. Cell Death Dis, 2023, 14 (10): 676. (并列一作)
6. Jiang Die, et al. Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases. Eur J Med Chem, 2023, 257: 115535. (并列一作)
7. Peng XR, et al. Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways. Cancer Chemother Pharmacol, 2023, 91 (4): 303-315. (通讯作者)
8. Zhao ZP, et al. Role of histone methyltransferase SETDB1 in regulation of tumourigenesis and immune response. Front Pharmacol, 2022, 13: 1073713. (通讯作者)
9. Zhong Lei, et al. Recent advances in small-molecular therapeutics for COVID-19. Precision Clinical Medicine, 2022, 5: pbac024.
10. Peng XR, et al. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges. Drug Des Devel Ther, 2022, 16: 2639-2657. (通讯作者)
11. Zhong Lei, et al. Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives. Signal Transduction and Targeted Therapy, 2021, 6: 201.
12. Yang ZY, et al. Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening and activity evaluation. Bioorg Med Chem Lett, 2021,33: 127745. (通讯作者)
13. Peng XR et al. Targeting H3K36 methyltransferases NSDs: a promising strategy for tumor targeted therapy, Signal Transduction and Targeted Therapy, 2021, 6 (1): 0-220. (通讯作者)
14. Su Lingyu, et al. Anti-oral squamous cell carcinoma effects of a potent TAZ inhibitor AR-42. Journal of Cancer, 2020, 11(2): 364-373. (通讯作者)
15. Peng Qian, et al. Association of elevated Yes-associated protein expression with gastric cancer and its clinicopathological features. J Biosci Med, 2020, 8, 96-109. (通讯作者)
16. Zhong Lei, et al. Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma. Investigational New Drugs, 2019, 37: 616-624.
17. Zhou Yanping, et al. Design, synthesis and in vitro tumor cytotoxicity evaluation of 3,5-diamino-N-substituted benzamide derivatives as novel GSK-3β small molecule inhibitors. Chem. Biodiversity, 2019, 16: e1900304. (通讯作者)
18. Zhong Lei, et al. Protective effect of ethyl vanillin against Aβ induced neurotoxicity in PC12 cells via the reduction of oxidative stress and apoptosis Experimental and Therapeutic Medicine, 2019, 17: 2666-2674.
19. Zhong Lei, et al. Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidinebased chemotherapy in colorectal cancer: a systematic review and meta-analysis. Oncotarget, 2018, 9 (58): 31291-31301.
20. Yang Ling-Ling, et al. X-ray crystal structure guided discovery of new selective, substratemimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells. European Journal of Medicinal Chemistry, 2018, 155: 806-823. (并列一作)
21. Zhong Lei, et al. Relevance of MTHFR polymorphisms with response to floropyrimidine based chemotherapy in oesophagogastric cancer: a meta-analysis. BMJ Open, 2018, 8: e020767.
22. Zhong Lei, et al. Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer. Oncotarget, 2017, 8 (8): 12843-12854.
23. Zhong Lei, et al. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma. International Journal of Cancer, 2014, 135 (12): 2972-2983.
24. Zhong Lei, et al. A prediction model of substrates and non-substrates of breast cancer Resistance protein (BCRP) developed by GA–CG –SVM method. Computers in Biology and Medicine, 2011, 41 (11): 1006-1013.
|
|
专业研究方向:
|
专业名称 |
研究领域/方向 |
招生类别 |
105500药学 |
02药物研究与转化 |
硕士专业学位 |
|
|
|
|
|
|
|